KR20220024098A - 요법에 사용하기 위한 parp14의 표적화된 단백질 분해 - Google Patents

요법에 사용하기 위한 parp14의 표적화된 단백질 분해 Download PDF

Info

Publication number
KR20220024098A
KR20220024098A KR1020217041538A KR20217041538A KR20220024098A KR 20220024098 A KR20220024098 A KR 20220024098A KR 1020217041538 A KR1020217041538 A KR 1020217041538A KR 20217041538 A KR20217041538 A KR 20217041538A KR 20220024098 A KR20220024098 A KR 20220024098A
Authority
KR
South Korea
Prior art keywords
alkyl
methyl
compound
pharmaceutically acceptable
thio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217041538A
Other languages
English (en)
Korean (ko)
Inventor
로리 비. 쉔켈
멜리사 마리 바스빈더
케빈 웨인 쿤츠
케런 칼라이 스윙어
티모시 제이. 엔. 위글
Original Assignee
리본 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리본 테라퓨틱스 인코포레이티드 filed Critical 리본 테라퓨틱스 인코포레이티드
Publication of KR20220024098A publication Critical patent/KR20220024098A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217041538A 2019-06-19 2020-06-18 요법에 사용하기 위한 parp14의 표적화된 단백질 분해 Pending KR20220024098A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863357P 2019-06-19 2019-06-19
US62/863,357 2019-06-19
PCT/US2020/038377 WO2020257416A1 (en) 2019-06-19 2020-06-18 Targeted protein degradation of parp14 for use in therapy

Publications (1)

Publication Number Publication Date
KR20220024098A true KR20220024098A (ko) 2022-03-03

Family

ID=71527971

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217041538A Pending KR20220024098A (ko) 2019-06-19 2020-06-18 요법에 사용하기 위한 parp14의 표적화된 단백질 분해

Country Status (11)

Country Link
US (2) US20220388985A1 (enExample)
EP (1) EP3986887A1 (enExample)
JP (2) JP2022537349A (enExample)
KR (1) KR20220024098A (enExample)
CN (2) CN114206853A (enExample)
AU (1) AU2020296063B2 (enExample)
BR (1) BR112021025645A2 (enExample)
CA (1) CA3142002A1 (enExample)
MA (1) MA56513A (enExample)
SG (1) SG11202112980TA (enExample)
WO (1) WO2020257416A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2941818T3 (es) * 2017-12-21 2023-05-25 Ribon Therapeutics Inc Quinazolinonas como inhibidores de PARP14
WO2022150667A1 (en) * 2021-01-08 2022-07-14 The Board Of Regents Of The University Of Texas System Nimbolide analogs and methods of use thereof
TW202241426A (zh) * 2021-01-29 2022-11-01 美商律幫治療股份有限公司 治療發炎疾病之方法
CN114890989B (zh) * 2022-05-25 2024-03-22 广东晨康生物科技有限公司 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用
CN117229224B (zh) * 2022-06-07 2026-05-08 中国药科大学 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用
MA71624A (fr) 2022-07-29 2025-05-30 Abbvie Operations Singapore Pte. Ltd. Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
KR20250055508A (ko) 2022-07-29 2025-04-24 애브비 오퍼레이션즈 싱가포르 피티이. 리미티드 치료에 사용하기 위한 parp14의 표적 단백질 분해
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
WO2024251205A1 (zh) * 2023-06-06 2024-12-12 西藏海思科制药有限公司 一种喹唑啉酮衍生物及其在医药上的应用
CN116813640A (zh) * 2023-06-29 2023-09-29 成都金瑞基业生物科技有限公司 一类抑制并降解parp的化合物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508414A (ja) * 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
EP2890696A1 (en) * 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
MY180775A (en) * 2014-04-23 2020-12-09 Incyte Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
EP3535265A4 (en) * 2016-11-01 2020-07-08 Arvinas, Inc. PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
EP3580212A4 (en) * 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. REGULATION OF CHEMERIC ANTIGEN RECEPTORS
EP4310496A3 (en) * 2017-07-12 2024-12-04 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
ES2941818T3 (es) * 2017-12-21 2023-05-25 Ribon Therapeutics Inc Quinazolinonas como inhibidores de PARP14

Also Published As

Publication number Publication date
JP7844707B2 (ja) 2026-04-13
MA56513A (fr) 2022-04-27
US20260125362A1 (en) 2026-05-07
EP3986887A1 (en) 2022-04-27
WO2020257416A1 (en) 2020-12-24
AU2020296063A1 (en) 2021-12-23
BR112021025645A2 (pt) 2022-02-01
AU2020296063B2 (en) 2026-01-29
SG11202112980TA (en) 2021-12-30
CN114206853A (zh) 2022-03-18
CA3142002A1 (en) 2020-12-24
CN120398840A (zh) 2025-08-01
US20220388985A1 (en) 2022-12-08
JP2022537349A (ja) 2022-08-25
JP2025102917A (ja) 2025-07-08

Similar Documents

Publication Publication Date Title
US20260125362A1 (en) Targeted protein degradation of parp14 for use in therapy
KR102835667B1 (ko) Parp14 억제제로서의 퀴나졸리논
KR102958021B1 (ko) 피리다지닐 티아졸카르복시아미드 화합물
CA3094336A1 (en) Compounds and methods for ido and tdo modulation, and indications therefor
EP3294297B1 (en) Pyrimidinone amide compounds as pde2 inhibitors
JP2019501954A (ja) １，４−ジカルボニル−ピペリジル誘導体
TW202417434A (zh) 用於治療之parp14之靶向蛋白質降解
HK40039341B (en) Quinazolinones as parp14 inhibitors
HK40039341A (en) Quinazolinones as parp14 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R19-X000 Request for party data change rejected

St.27 status event code: A-3-3-R10-R19-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701